Myriad Genetics: SOTP Suggests The Company Is Undervalued

Estimated value of about $6.05 per share versus the current market price indicates the stock is likely undervalued. The core Hereditary Cancer franchise is the strongest unit, showing more resilient volumes and steadier operating performance, while weak earnings and cash flow keep the market multiple low. A conservative sum-of-the-parts plus potential portfolio simplification could unlock additional upside for equity holders.

Analysis

Winners from an operational reset will not be limited to the stock — lab services and mid-sized oncology practices that buy or license stable hereditary panels stand to gain pricing/volume leverage if Myriad simplifies and monetizes non-core assets. Instrument and reagent suppliers (sequencing consumables, automation vendors) will see steadier demand if management re-centers on high-throughput hereditary volumes, while nimble regional competitors could be squeezed if scale advantages are re-asserted.

Key catalysts cluster into short and medium windows: near-term (weeks–months) earnings/quarterly commentary that quantifies margin pathway and cash conversion; medium-term (6–18 months) corporate actions — asset sales, JV or targeted M&A — that re-rate the business. Primary tail risks are policy-driven (payer coverage reversals or CPT re-pricing) and tech disruption from lower-cost NGS entrants; either could compress EBITDA by 20–50% relative to base expectations within 12–24 months.

A pragmatic trade framework mixes equity exposure with optionality: accumulate on post-earnings dips sized to 3–5% NAV with a 25–35% stop, and overlay long-dated calls to capture upside from a successful simplification or bid process. Hedging via a short position in a diagnostic peer with weaker balance sheet or higher execution risk reduces sector beta and isolates Myriad-specific outcomes.

Contrarian read: the market appears to be conflating temporary cash-flow volatility with permanent loss of franchise economics — if management demonstrates credible cash conversion and a repeatable divestiture playbook, expect a compressed time-to-recovery (6–12 months). The bigger error would be treating this as a secular decline rather than an idiosyncratic reset that can be arbitraged via event-driven capital allocation trades.

Key Decisions for Investors

• Buy MYGN equity sized 3–5% of NAV on a <10% post-earnings retreat; target 12-month upside ~+50–70%, stop-loss 30% — rationale: event-driven re-rating if portfolio simplification materializes.
• Purchase MYGN Jan-2027 LEAP calls (~ATM) as a 1–2% NAV allocation to retain upside with defined downside (premium); expect asymmetric payoff if management pivots to cash return or attracts strategic buyer within 12–18 months.
• Pair trade: long MYGN / short Invitae (NVTA) equal-dollar for 6–12 months to isolate idiosyncratic execution — expected payoff 2:1 if Myriad stabilizes volumes while NVTA faces continued margin pressure; unwind on 25% net position move.
• Event-specific: add into a 3–6% position ahead of any announced portfolio sale or restructuring, then take partial profits (30–50%) on a confirmed bid/asset sale press release; maintain residual for operational re-rating over 12 months.